1-3 of 3
Femke Van Bockstaele
Close
Sort by
Journal Articles

Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs

Hans Ulrichts, Karen Silence, Anne Schoolmeester, Peter de Jaegere, Stefaan Rossenu, Jan Roodt, Sofie Priem, Marc Lauwereys, Peter Casteels, Femke Van Bockstaele, Katrien Verschueren, Patrick Stanssens, Judith Baumeister, Josefin-Beate Holz
Journal: Blood
Blood (2011) 118 (3): 757–765.
https://doi.org/10.1182/blood-2010-11-317859
Published: 2011
Includes: Supplemental data
Journal Articles

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Anti-Vwf Nanobody® ALX-0681 After Single and Multiple Subcutaneous Administrations to Healthy Volunteers.

Khalid Abd-Elaziz, Pieter W. Kamphuisen, Christophe Lyssens, Mariska Reuvers, Izaak den Daas, Femke Van Bockstaele, Kristof Vercruysse, Hans Ulrichts, Judith Baumeister, Patricia Crabbe, Veerle Compernolle, Josefin-Beate Holz
Journal: Blood
Blood (2009) 114 (22): 1063.
https://doi.org/10.1182/blood.V114.22.1063.1063
Published: 2009
Journal Articles

The Restricted V H -Gene Usage Is of Prognostic Value in B-Cell Chronic Lymphocytic Leukemia.

Jan Philippé, MD, PhD, Femke Van Bockstaele, Kaatje Smits, Fritz Offner, MD, PhD, Bruno Verhasselt, MD, PhD, Ann Janssens, MD
Journal: Blood
Blood (2004) 104 (11): 1911.
https://doi.org/10.1182/blood.V104.11.1911.1911
Published: 2004